Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Mercaptopurine (oral suspension)

EU orphan designation number: EU/3/09/628   
Active ingredient: Mercaptopurine (oral suspension)
Indication: Treatment of acute lymphoblastic leukaemia
Sponsor: Nova Laboratories Limited
Martin House, Gloucester Crescent, Wigston Leicester, LE18 4YL, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Xaluprine on 09/03/2012 with the number EU/1/11/727

   Public summary of scientific opinion     EPAR

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
05/05/2009 Centralised Orphan - Designation EMEA/OD/114/08 (2009)3527 of 30/04/2009